THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.10]-CMP159 ID: TIP-MED-000429

Drotaverine Hydrochloride IP

Active Ingredient / Scientific Identity: Drotaverine Hydrochloride IP • Class: Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smooth-Muscle Antispasmodic

⚖️ Compare Profile
Generic / Entity NameDrotaverine Hydrochloride IP ([12.10]-CMP159)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassCompetitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smooth-Muscle Antispasmodic
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-P
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Drotaverine Hydrochloride IP (TIP-MED-000429, Reference Code [12.10]-CMP159) is classified under Urological & Renal Stone Medicines (Ch 12) as a Competitive Muscarinic (M2/M3) Receptor Antagonists & Direct Smooth-Muscle Antispasmodic. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.11] & Inventory CSV mono-6-19; primary coverage at [7.16]).
Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.11] & Inventory CSV mono-6-19; primary coverage at [7.16]).
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.11] & Inventory CSV mono-6-19; primary coverage at [7.16]).

4. Therapeutic Indications & Evidence-Supported Uses

  • Overactive bladder (urge urinary incontinence, urgency, frequency), neurogenic detrusor overactivity (Oxybutynin), and symptomatic relief of dysuria, nocturia, and suprapubic cystitis/catheter spasm (Flavoxate)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-12 (Option 12A; from merged HTML [12.11] & Inventory CSV mono-6-19; primary coverage at [7.16]).

Administration & Meal Timing: Take Flavoxate after meals to prevent nausea; swallow Tolterodine ER capsules whole with water. | Once daily (Tolterodine ER) or BD/TDS (IR formulations & Flavoxate).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.10].
Metabolism & Biotransformation:
Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.
Elimination & Renal Adjustment:
Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.
Hepatic Impairment Considerations:
Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CONTRAINDICATED IN URINARY RETENTION, GASTRIC RETENTION & UNCONTROLLED NARROW-ANGLE GLAUCOMA: Oxybutynin is highly lipophilic, crosses the blood–brain barrier, and carries a high Anticholinergic Cognitive Burden (ACB Score = 3 — avoid in frail elderly/dementia per AGS Beers 2023; prefer Mirabegron or Solifenacin).

Key Clinical Precautions: Renal: Reduce Tolterodine to 1 mg BD (or 2 mg ER OD) if CrCl <30 mL/min. Hepatic: Reduce Tolterodine to 1 mg BD in Child-Pugh B; avoid in Child-Pugh C.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Dry mouth (xerostomia — up to 35–70% with Oxybutynin), constipation, blurred vision, dry eyes, drowsiness, dizziness, heat intolerance (anhidrosis).
  • Acute urinary retention (especially in men with BPH), delirium/cognitive decline in older adults, acute angle-closure glaucoma, QTc prolongation (Tolterodine).
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • CYP3A4 inhibitors (Clarithromycin, Itraconazole, Ketoconazole) double Tolterodine/Oxybutynin levels (cap Tolterodine at 2 mg/day)
    • Antagonises cholinesterase inhibitors (Donepezil — 'prescribing cascade' worsening dementia!)

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.10].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Sip water or use sugar-free lozenges for dry mouth; avoid overheating in Indian summer weather (reduced sweating); report difficulty passing urine or confusion in elderly patients immediately.
    • Meal & Clock Timing Instruction: Take Flavoxate after meals to prevent nausea; swallow Tolterodine ER capsules whole with water. (Once daily (Tolterodine ER) or BD/TDS (IR formulations & Flavoxate).)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM (Standard Urology OPD) | Compendia: NFI 7th Ed 2026 / AGS Beers Criteria 2023

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tolterodine IR Tablets: 1 mg, 2 mg; ER Capsules: 2 mg, 4 mg. Oxybutynin Tablets: 2.5 mg, 5 mg (Scored), 5 mg ER. Flavoxate Film-Coated Tablets: 200 mg.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.